Transferrin-conjugated doxorubicin-loaded lipid-coated nanoparticles for the targeting and therapy of lung cancer

Oncology Letters

Volumn 9, Issue 3, 2015, Pages 1065-1072

  Guo, Yajun ^a   Wang, Lijuan ^a   Lv, Peng ^b   Zhang, Peng ^b  

^a ZHENGZHOU UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Doxorubicin; Lung cancer; Transferrin; Tumor targeting

Indexed keywords

DOXORUBICIN; LIPID COATED NANOPARTICLE; NANOPARTICLE; POLYGLACTIN; TRANSFERRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC50; LUNG CANCER; MALE; MOUSE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; PARTICLE SIZE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

EID: 84921714578     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2840     Document Type: Article

References (25)

1. Jinturkar KA, Anish C, Kumar MK, et al: Liposomal formulations of Etoposide and Docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. Biomaterials 33: 2492-2507, 2012.
2. Sengupta S, Tyagi P, Velpandian T, et al: Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies. Pharmacol Res 42: 459-464, 2000.
3. Li R, Zhang Q, Wang XY, et al: A targeting drug delivery system for ovarian carcinoma: transferring modified lipid coated paclitaxel-loaded nanoparticles. Drug Res (Stuttg) 64: 541-547, 2014.
4. Oh S, Kim BJ, Singh NP, et al: Synthesis and anti-cancer activity of covalent conjugates of artemisinin and a transferrin-receptor targeting peptide. Cancer Lett 274: 33-39, 2009.
5. Hu CM and Zhang L: Therapeutic nanoparticles to combat cancer drug resistance. Curr Drug Metab 10: 836-841, 2009.
6. Torchilin VP: Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4: 145-160, 2005.
7. Wang AZ, Bagalkot V, Vasilliou CC, et al: Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem 3: 1311-1315, 2008.
8. Nakatsuji T, Kao MC, Zhang L, et al: Sebum free fatty acids enhance the innate immune defense of human sebocytes by upregulating beta-defensin-2 expression. J Invest Dermatol 130: 985-994, 2010.
9. Hu CM, Kaushal S, Tran Cao HS, et al: Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol Pharm 7: 914-920, 2010.
10. Kibria G, Hatakeyama H, Ohga N, et al: Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery. J Control Release 153: 141-148, 2011.
11. Sharma G, Modgil A, Sun C and Singh J: Grafting of cell-penetrating peptide to receptor-targeted liposomes improves their transfection efficiency and transport across blood-brain barrier model. J Pharm Sci 101: 2468-2478, 2012.
12. Wadia JS and Dowdy SF: Protein transduction technology. Curr Opin Biotechnol 13: 52-56, 2002.
13. Wang H, Zhao Y, Wu Y, et al: Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 32: 8281-8290, 2011.
14. Cui Y, Xu Q, Chow PK, et al: Transferrin-conjugated magnetic silica PLGA nanoparticles loaded with doxorubicin and paclitaxel for brain glioma treatment. Biomaterials 34: 8511-8520, 2013.
15. Chan JM, Zhang L, Yuet KP, et al: PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 30: 1627-1634, 2009.
16. Zhang L, Chan JM, Gu FX, et al: Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2: 1696-1702, 2008.
17. Yang X, Koh CG, Liu S, et al: Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. Mol Pharm 6: 221-230, 2009.
18. Chiu SJ, Liu S, Perrotti D, et al: Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J Controlled Release 112: 199-207, 2006.
19. Jiang T, Zhang Z, Zhang Y, et al: Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 33: 9246-9258, 2012.
20. Maeda N, Takeuchi Y, Takada M, et al: Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J Control Release 100: 41-52, 2004.
21. Lewis CE and Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605-612, 2006.
22. Fukumura D, Xu L, Chen Y, Gohongi T, et al: Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 61: 6020-6024, 2001.
23. Jain RK: Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 64 (Suppl): 353-365, 2012.
24. Wang X, Yang L, Chen ZG and Shin DM: Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin 58: 97-110, 2008.
25. Chen X, Wang X, Wang Y, et al: Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release 145: 17-25, 2010.